Vision

Myopia Progression

Explore information focused on myopia progression and its place within vision health.

2What may help

This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.

What may help

What studies found for each option, best evidence first.

2 options:1 some evidence1 no benefit found

What studies foundSize of effect

Red Light Therapy (Photobiomodulation)practiceSome evidence it helpsSize of effect: Not known
Some human studies found a benefit. More research could change this.
All 2 studies with a clear result found a benefit.
A pooled analysis of 41 randomized trials reported that repeated low-level red-light therapy slowed axial length elongation and spherical equivalent progression compared with control. A separate analysis of 9 randomized trials also reported reductions in both measures.
Open the Red Light Therapy (Photobiomodulation) page
Alternate Nostril Breathing (Nadi Shodhana)practiceNo benefit found
Studies looked for a benefit and did not find one.
The one study found no benefit.
A randomized controlled trial involving 60 people found that 3 months of yoga therapy did not reduce changes in visual acuity or clinical refraction; only associated symptoms improved.
Open the Alternate Nostril Breathing (Nadi Shodhana) page

The expert view shows every study, dose protocol and source.

What may help

Interventions recorded as helping with this condition2 listed

Most likely to help, from the evidence we have

PracticesRed Light Therapy (Photobiomodulation)CertaintyMediumSourceMeta-analysis
A pooled analysis of 41 randomized trials reported that repeated low-level red-light therapy slowed axial length elongation and spherical equivalent progression compared with control. A separate analysis of 9 randomized trials also reported reductions in both measures.
Who was studied
People with a condition
Myopia Progression
Study result
Network meta-analysis of 41 RCTs showing RLRL significantly slows axial length elongation and spherical equivalent progression compared with control.
Open Red Light Therapy (Photobiomodulation)
→

Very low probability(1)

PracticesAlternate Nostril Breathing (Nadi Shodhana)CertaintyVery lowSourceClinical
A randomized controlled trial involving 60 people found that 3 months of yoga therapy did not reduce changes in visual acuity or clinical refraction; only associated symptoms improved.
Who was studied
People with a condition
Myopia Progression
Open Alternate Nostril Breathing (Nadi Shodhana)
→

What to avoid

Interventions recorded as making it worse

Nothing in this library is currently recorded as making Myopia Progression worse. Coverage is partial, and absence here is not evidence of safety.

Browse the supplements that are written up

How to read the evidence

Evidence tier — overall strength of the evidence for the whole compound

StrongWell established — backed by strong, consistent human research.
ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
LimitedVery limited evidence — treat this as a hypothesis, not proof.
InsufficientNot enough good evidence to draw conclusions yet.

Certainty — how sure we can be that the effect is real

Very highVery sure — strong, consistent evidence
HighFairly sure — consistent evidence from good studies
MediumModerately sure — new studies could change this
LowNot sure — little or mixed evidence
Very lowVery unsure — almost no usable evidence

Source — where the data comes from

Meta-analysisPooled analysis of many trials — the strongest evidence
RCTRandomized controlled trial — a strong human study design
ClinicalA human clinical study
Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
Animal researchStudied in animals, not humans
Community reportsAggregated user reports — anecdotal signal, not evidence
TheoreticalMechanism-based reasoning, not yet tested

Study grade — quality of each underlying study (A best, D weakest)

AHigh-quality — strong, consistent human trials
BGood — solid evidence with some limitations
CModerate — limited, small, or mixed-quality studies
DWeak — preliminary, indirect, or animal-only

Confidence — how strongly the sources back a finding

A 0–100 score from study quality and agreement

Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.

Full write-up

What is it

Myopia progression is a vision-health outcome concerned with whether measures linked to myopia change over time. In this context, it involves spherical equivalent refraction (SER) and axial length (AL), rather than choroidal changes alone. This distinction matters because an intervention may affect choroidal thinning without producing significant changes in SER or AL. The outcome should therefore be interpreted separately from changes in choroidal thickness.

Evidence-backed options

Lutein was studied as a lutein ester supplement over six months. During that period, supplementation was associated with suppression of choroidal thinning, but there were no significant changes in spherical equivalent refraction (SER) or axial length (AL) compared with the control group.

The finding therefore relates to a structural eye measure rather than a demonstrated change in the refractive or eye-length outcomes used to assess myopia progression. The information available does not establish how quickly any effect appeared; six months is the duration examined. It also does not show whether the findings apply to particular age groups, baseline myopia levels, or other health statuses, because the studied health status was not specified.

These results are best interpreted as limited to the outcomes and timeframe examined, not as confirmation that lutein prevents or reverses myopia progression. A clinician can help place this evidence in the context of an individual medical situation.